PharmaResources (Shanghai) Financials
| 301230 Stock | 37.16 1.22 3.39% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 53.8 M | 38.7 M |
|
|
PharmaResources | Select Account or Indicator |
Understanding current and past PharmaResources (Shanghai) Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of PharmaResources (Shanghai)'s financial statements are interrelated, with each one affecting the others. For example, an increase in PharmaResources (Shanghai)'s assets may result in an increase in income on the income statement.
Please note, the presentation of PharmaResources (Shanghai)'s financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, PharmaResources (Shanghai)'s management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of PharmaResources (Shanghai)'s management manipulating its earnings.
PharmaResources (Shanghai) Stock Summary
PharmaResources (Shanghai) competes with Goldlok Toys, INKON Life, Tianjin Silvery, Guocheng Mining, and ISoftStone Information. PharmaResources is entity of China. It is traded as Stock on SHE exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | China Stock View All |
| Exchange | Shenzhen Stock Exchange |
| ISIN | CNE1000065Q9 |
| Business Address | Building 12, Shanghai, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.pharmaresources.cn |
You should never invest in PharmaResources (Shanghai) without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of PharmaResources Stock, because this is throwing your money away. Analyzing the key information contained in PharmaResources (Shanghai)'s financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
PharmaResources (Shanghai) Key Financial Ratios
PharmaResources (Shanghai)'s financial ratios allow both analysts and investors to convert raw data from PharmaResources (Shanghai)'s financial statements into concise, actionable information that can be used to evaluate the performance of PharmaResources (Shanghai) over time and compare it to other companies across industries.| Revenue | 489.72 M | ||||
| Gross Profit | 105 M | ||||
| Net Income | 37.62 M | ||||
| Total Asset | 1.49 B | ||||
| Retained Earnings | 186.3 M |
PharmaResources Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining PharmaResources (Shanghai)'s current stock value. Our valuation model uses many indicators to compare PharmaResources (Shanghai) value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PharmaResources (Shanghai) competition to find correlations between indicators driving PharmaResources (Shanghai)'s intrinsic value. More Info.PharmaResources Co Ltd is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value PharmaResources (Shanghai) by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for PharmaResources (Shanghai)'s Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.PharmaResources (Shanghai) Systematic Risk
PharmaResources (Shanghai)'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. PharmaResources (Shanghai) volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on PharmaResources (Shanghai) correlated with the market. If Beta is less than 0 PharmaResources (Shanghai) generally moves in the opposite direction as compared to the market. If PharmaResources (Shanghai) Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one PharmaResources (Shanghai) is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of PharmaResources (Shanghai) is generally in the same direction as the market. If Beta > 1 PharmaResources (Shanghai) moves generally in the same direction as, but more than the movement of the benchmark.
PharmaResources Co Ltd Total Assets Over Time
PharmaResources (Shanghai) March 7, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of PharmaResources (Shanghai) help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of PharmaResources Co Ltd. We use our internally-developed statistical techniques to arrive at the intrinsic value of PharmaResources Co Ltd based on widely used predictive technical indicators. In general, we focus on analyzing PharmaResources Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build PharmaResources (Shanghai)'s daily price indicators and compare them against related drivers.
| Downside Deviation | 3.12 | |||
| Information Ratio | 0.1454 | |||
| Maximum Drawdown | 30.86 | |||
| Value At Risk | (5.71) | |||
| Potential Upside | 8.41 |
Complementary Tools for PharmaResources Stock analysis
When running PharmaResources (Shanghai)'s price analysis, check to measure PharmaResources (Shanghai)'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaResources (Shanghai) is operating at the current time. Most of PharmaResources (Shanghai)'s value examination focuses on studying past and present price action to predict the probability of PharmaResources (Shanghai)'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaResources (Shanghai)'s price. Additionally, you may evaluate how the addition of PharmaResources (Shanghai) to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |